📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 60mg | 240 pills | A$1.84 | A$440.98 Best Price | |
| 60mg | 180 pills | A$1.91 | A$343.47 | |
| 60mg | 120 pills | A$2.06 | A$248.18 | |
| 60mg | 90 pills | A$2.17 | A$194.99 | |
| 60mg | 60 pills | A$2.33 | A$139.59 | |
| 60mg | 30 pills | A$2.64 | A$79.76 | |
| 90mg | 240 pills | A$2.86 | A$686.97 | |
| 90mg | 180 pills | A$2.90 | A$522.98 | |
| 90mg | 120 pills | A$2.97 | A$356.77 | |
| 90mg | 90 pills | A$3.10 | A$279.21 | |
| 90mg | 60 pills | A$3.26 | A$194.99 | |
| 90mg | 30 pills | A$3.50 | A$104.13 | |
| 120mg | 240 pills | A$3.32 | A$797.77 Popular | |
| 120mg | 180 pills | A$3.39 | A$609.40 | |
| 120mg | 120 pills | A$3.46 | A$414.39 | |
| 120mg | 90 pills | A$3.63 | A$327.96 | |
| 120mg | 60 pills | A$3.81 | A$228.24 | |
| 120mg | 30 pills | A$4.08 | A$121.86 |
Disclaimer: This information is intended for educational use and should complement professional medical advice. For individual guidance on suitability and dosing of arcoxia in Australia, consult a pharmacist or clinician.
Arcoxia is the brand name for etoricoxib, a non-steroidal anti-inflammatory drug (NSAID) with selective activity on the COX‑2 enzyme. The active ingredient is etoricoxib, and the medicine is used to relieve pain and inflammation in adults. This preparation is intended to treat symptoms associated with inflammatory and degenerative conditions, with the aim of improving comfort and mobility.
As a COX‑2 selective NSAID, Arcoxia works by reducing the production of prostaglandins at sites of inflammation, which helps lower pain and swelling. The selectivity refers to the way the drug interacts with the enzyme systems, potentially influencing the pattern of side effects compared with non‑selective NSAIDs. The risk profile still includes possible adverse effects, and individual risk should be discussed with a clinician or pharmacist.
In the Australian setting, Arcoxia may be prescribed to adults when a clinician judges that the benefits for pain relief and function outweigh potential risks. The decision is guided by medical history, current medications, and overall health status. Adherence to the prescribed plan and regular follow‑up are important to monitor response and safety.
Arcoxia tablets are taken by mouth, under medical supervision. A pharmacist or clinician can provide detailed instructions about timing relative to meals, and about whether to take the medicine with other therapies. The medicine is not intended for use in children, and access may depend on local prescribing rules.
Arcoxia is used to manage pain and inflammation associated with several inflammatory or degenerative joint and connective tissue disorders. The aim is to reduce daily pain, stiffness, and functional limitation that compromise activity and quality of life. A clinician will determine whether Arcoxia is an appropriate option within a broader treatment plan.
In practice, Arcoxia may be considered for conditions that involve chronic or acute inflammatory pain, particularly when joint or spinal symptoms are prominent. The medication is often used when first‑line analgesics have not provided sufficient relief, or when a clinician reasons that a COX‑2 selective approach offers a suitable balance of benefit and risk for the patient.
Typical targets for relief include conditions affecting joints and the spine, where inflammation contributes to symptoms such as pain, morning stiffness, and swelling. The response to treatment varies between individuals and may depend on disease activity, duration of use, and concomitant therapies. The following representative conditions are commonly considered in treatment discussions:
The body produces prostaglandins as part of the normal response to injury or inflammation. These chemical mediators contribute to pain, swelling, and warmth in affected areas. Arcoxia inhibits the COX‑2 enzyme, which is involved in producing many of these prostaglandins at sites of inflammation. By dampening this production, pain and inflammation can lessen, allowing improved function in many patients.
The selective action on COX‑2 means that Arcoxia is designed to minimize some of the stomach-related irritation that can occur with non‑selective NSAIDs. Nevertheless, prostaglandin pathways also support protective mechanisms in the stomach lining, so GI adverse effects remain possible. The overall effect is a reduction in inflammatory pain with attention to safety concerns specific to COX‑2 inhibitors.
Relief from pain does not imply a cure; long‑standing conditions may require ongoing assessment and adjustments to therapy. The mechanism of action also informs the need to monitor for signs of adverse effects, particularly in patients with additional risk factors or those taking other medicines. A clinician may order periodic reviews to ensure continued appropriateness.
Understanding these mechanisms supports clear conversations with healthcare professionals about expectations, alternatives, and any needed precautions during treatment with Arcoxia. The information provided here is intended to support informed decisions, not to replace personalized medical advice.
Arcoxia should be taken exactly as prescribed by a clinician. The dosing regimen is individualized based on the condition being treated, the severity of symptoms, and the patient’s overall health. The tablet form is intended for oral use with water, and should not be chewed or crushed unless specifically instructed by a clinician.
Timing and method of administration may be adjusted to suit daily routines. In many cases, once‑daily dosing is used, with or without food depending on tolerability and specific medical considerations. If advice about meals is given, it should be followed to help minimise stomach upset and maximise tolerability.
If a dose is missed, the patient should take it as soon as remembered, unless it is near the time of the next dose. In that case, the next dose should be taken at the scheduled time, and no double dosing should be attempted. If there are concerns about missed doses, contact a pharmacist for guidance. Do not alter the prescribed plan without professional consultation.
Duration of use is determined by the treating clinician. Short‑term use may be appropriate for acute pain, whereas longer periods of therapy require ongoing medical assessment. New symptoms, reduced effectiveness, or emerging adverse effects should be discussed with a clinician promptly to decide on continuation or modification of therapy.
Arcoxia may not be suitable for every individual. The medicine should not be used when there are specific medical conditions or circumstances that increase risk. A clinician will assess risk factors and determine suitability before starting therapy.
Contraindications include situations where a known allergy to etoricoxib or similar medicines is present, or where active or recent gastrointestinal bleeding or ulcers have occurred. Caution is warranted in those with significant kidney or liver impairment, or with certain cardiovascular conditions. The use in children and adolescents under 18 years is generally not indicated unless advised by a clinician.
Other contraindications include pregnancy in later stages or breastfeeding without medical guidance, and situations where the potential benefits do not justify the risks due to comorbidities or concurrent medications. If any of these scenarios apply, the patient should not initiate therapy and should consult a pharmacist or clinician for alternatives. Access to this medicine may require a prescription depending on local rules.
Before initiating therapy, a clinician will review medical history for risk factors associated with NSAIDs, including past GI events, kidney disease, liver disease, and hypertension. Continuous monitoring may be required during long‑term treatment to detect adverse effects early. If any new and persistent symptoms appear, medical advice should be sought promptly.
Cardiovascular safety is an important consideration with COX‑2 inhibitors. The risk of heart attack or stroke may be increased with higher doses or prolonged use, particularly in patients with existing cardiovascular risk factors. The medicine should be used at the lowest effective dose for the shortest possible duration, and patients should be advised to report chest pain, weakness, sudden headaches, or confusion promptly.
Gastrointestinal toxicity, including bleeding, ulcers, and perforation, can occur with NSAIDs at any time during therapy. The risk may be higher in older adults or those with a history of GI problems. If there are signs of GI bleeding, such as passing dark stools or vomiting blood, urgent medical assessment is required. A clinician may consider protective strategies or alternative therapies for high‑risk individuals.
Renal and hepatic function can be affected by NSAIDs. Dehydration, concurrent use of certain medicines, or preexisting kidney or liver impairment may increase risk. Regular monitoring and dose adjustments may be needed. If there is a noticeable change in urine output, swelling, jaundice, or unusually dark urine, medical advice should be sought promptly.
Allergic reactions can occur with Arcoxia, though they are uncommon. Signs may include rash, itching, swelling, or breathing difficulties. In the event of suspected anaphylaxis or severe allergic reaction, seek urgent medical help. The use of Arcoxia should be stopped if an allergic reaction is suspected and medical evaluation obtained.
All medications can interact with Arcoxia. The clinician will review current medicines to minimize interaction risk. Patients should inform all healthcare providers about Arcoxia use, especially before starting new prescriptions, over‑the‑counter products, or herbal supplements. Caution is advised in those who consume alcohol regularly, as GI and liver effects may be amplified.
As with other medicines, Arcoxia can cause side effects in some individuals. The majority of reactions are mild to moderate and reversible after stopping therapy. If any adverse effects appear, consultation with a pharmacist or clinician is recommended to assess severity and the need for treatment adjustments.
Common side effects are typically related to the gastrointestinal tract or the nervous system and may include symptoms such as stomach upset, indigestion, heartburn, dizziness, or headache. These effects often improve with time or after dose adjustments guided by a clinician. Persistent or worsening symptoms warrant medical advice.
Less common but more serious adverse effects can include signs of GI bleeding, severe rash, swelling of the ankles or hands, yellowing of the skin or eyes, dark urine, or reduced urine output. If any of these occur, emergency medical assessment is necessary. The risk of serious skin reactions, while rare, requires immediate professional evaluation if a rash or mucosal changes develop.
Allergic reactions to Arcoxia are possible and may present with wheeze, swelling of the lips or tongue, or severe skin reactions. In case of any suspected reaction, the medicine should be stopped and professional help sought promptly. The information provided here supports safety monitoring but does not replace individualized medical advice.
Arcoxia may interact with other medicines, foods, and supplements, potentially altering effectiveness or increasing the risk of adverse effects. A clinician will review current therapies to identify potential interactions before starting therapy and will provide personalised guidance. Patients should always disclose all medicines to the pharmacist when obtaining Arcoxia.
Important interactions may involve other NSAIDs and anticoagulants, which can raise the risk of bleeding. Concurrent use with certain antidepressants or drugs affecting kidney function may also require monitoring. These interactions are not necessarily contraindications but may necessitate adjustments in dosing or monitoring plans.
Alcohol use and certain herbal products can increase GI irritation or liver burden when combined with NSAIDs. It is prudent to limit alcohol intake and to discuss any herbal or supplement use with a clinician. The aim is to minimise avoidable adverse effects and ensure safe therapy.
Because interactions vary with health status and complete medication lists, check with a pharmacist before adding new medicines, including over‑the‑counter products and vitamins. If any new medication is started or stopped, inform the clinician and pharmacist to reassess Arcoxia therapy accordingly.
Use of Arcoxia during pregnancy is not routinely advised, especially in the later stages of gestation, unless the potential benefits clearly outweigh the risks as determined by a clinician. If pregnancy is planned or suspected, medical advice should be sought promptly to discuss alternatives and timing. The safety profile has not established safety in all stages of pregnancy.
Breastfeeding is another consideration requiring professional advice. It is not known whether Arcoxia passes into breast milk in meaningful amounts, and the potential effects on the infant are not fully established. A clinician will weigh the benefits to the mother against any potential risk to the breastfed infant and may suggest an alternative therapy or a plan for breastfeeding cessation during treatment if necessary.
In all scenarios, the decision to use Arcoxia during pregnancy or while breastfeeding should involve a careful discussion with a clinician. If pregnancy occurs while taking Arcoxia, or if there is any intent to become pregnant during therapy, seek medical guidance to review options and modify treatment if needed. It is important to avoid making changes without professional advice.
Paracetamol is commonly used alongside NSAIDs for additional pain relief in some patients, but concomitant use should be guided by a clinician. Interactions may occur with other analgesics or medicines that affect bleeding risk or kidney function. Do not start, stop, or adjust any medicine without professional advice. If there are concerns about combinations, consult a pharmacist before taking multiple products.
If a dose is missed, take it as soon as remembered unless it is close to the time for the next dose. Do not double the dose to make up for a missed one. If there are questions about missed doses or long gaps in therapy, contact a pharmacist or clinician for guidance. Do not adjust the schedule without professional input.
Relief of pain and inflammation can occur within hours after taking a dose, but the exact time to onset varies between individuals and conditions. Some patients may notice improvement sooner, while others may require several days of therapy. If expected benefits are not observed after a reasonable period, a clinician should be consulted for assessment and potential adjustments.
Long‑term use of Arcoxia requires careful consideration of benefits and risks, especially regarding cardiovascular, GI, renal, and hepatic safety. A clinician may determine that ongoing use is appropriate with regular checkups, dose adjustments, and monitoring tests. If new health concerns arise, contact a clinician promptly to reassess therapy.
Moderate or excessive alcohol use can increase the risk of GI irritation and other adverse effects when combined with NSAIDs. It is prudent to limit alcohol intake during therapy and to discuss any drinking patterns with a clinician. The safest approach is to follow medical advice tailored to the individual’s health status.
Arcoxia can influence blood pressure and kidney function in some patients, particularly those taking antihypertensive medicines. A clinician will assess cardiovascular risk and kidney function, and may monitor blood pressure and laboratory tests during treatment. Report any significant changes in blood pressure or swelling to a clinician promptly.
NSAIDs, including Arcoxia, can impact kidney function in some individuals, especially with dehydration, concurrent diuretic use, or preexisting kidney conditions. Regular monitoring may be recommended when therapy is prolonged or when risk factors exist. Seek medical advice if reduced urine output, swelling, or fatigue develops.
Use during pregnancy is generally avoided during the later stages unless specifically advised by a clinician, due to potential risks to the fetus. Breastfeeding considerations are similar; a clinician will weigh maternal benefits against potential infant exposure. If pregnancy occurs while taking Arcoxia, seek medical guidance promptly to review alternatives or timing.
Arcoxia use around the time of planned surgery or dental procedures requires coordination with the surgical or dental team. The clinician may provide instructions on whether to continue or temporarily discontinue therapy to reduce bleeding risk or interactions with anaesthesia. Do not stop or restart therapy without professional guidance.
Signs of an allergic reaction require immediate medical attention. These signs can include swelling of the face or throat, severe skin reactions, or breathing difficulties. In such cases, discontinue the medicine and seek urgent medical help. A clinician will determine the appropriate next steps and alternatives if needed.
The official patient information leaflet supplied with Arcoxia, and the accompanying product label, contain important details about dosing, warnings, and safe use. Those materials should be read carefully before starting therapy and re‑referenced during follow‑up appointments. If any information is unclear, request clarification from a pharmacist or clinician.
For additional information, consult the supervising clinician or local pharmacy team. They can explain how Arcoxia fits with other medicines, existing health conditions, and personal health goals. In Australia, regulatory bodies and the medicine sponsor provide formal information that can guide safe and informed use, and it is prudent to review these sources with a healthcare professional.
Do not rely on this leaflet alone for medical decisions. If there is uncertainty about indications, contraindications, or how to use Arcoxia in a specific health scenario, check the official patient leaflet, contact a pharmacist, or arrange an appointment with a clinician for personalised advice. Seek prompt medical attention if unexpected or severe symptoms occur during therapy.
14–21 days. Free from A$285.95 .
5–9 days. A$42.89
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
